Is Fortrea Holdings Inc. (FTRE) a Buy, Sell, or Hold?
Fortrea Holdings Inc.
NASDAQ:FTRE
$18.03 USD
$0.17 (0.95%)
- Volume
- 755.46K
- Average Volume
- 1.44M
- Market Capitalization
- $1.71B
- P/E Ratio
- -3.66
- Dividend Yield
- 0.00%
- Price Target
- $18.00
- Year High
- $18.67
- Year Low
- $4.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.95
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Anshul Thakral |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | FTRE |
| CUSIP | 34965K107 |
| CIK | 0001965040 |
| Web | https://www.fortrea.com |
| Phone | (480)-295-7600 |
| Currency | USD |
| Employees | 14300 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.13 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.95 |
| Quick Ratio | 0.95 |
| Cash Ratio | 0.16 |
Sales & Book Value
| Annual Sales | $2.72B |
| Price / Sales | 0.63 |
| Cash Flow | 2.09 |
| Price / Cash Flow | 8.96 |
| Price / Book | 3.13 |
Price Target and Rating
| Average Stock Price Forecast | $18.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | 0.17% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 12 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-10.81 |
| Trailing P/E Ratio | -3.66 |
| PEG Ratio | -0.26 |
| P/E Growth | -0.26 |
| Net Income | $-986.2M |
| Net Margin | -16.50% |
| Pretax Margin | -16.51% |
| Return on Equity | -79.12% |
| Return on Assets | -16.65% |
Financials Score
| AltmanZ Score | 0.28 |
| Piotroski Score | 4.00 |
| Working Capital | -47.6M |
| Total Assets | 2.68B |
| Ebit | -359.4M |
| Market Cap | 1.69B |
| Total Liabilities | 2.16B |
Poll Results
About Fortrea Holdings Inc. (NASDAQ:FTRE) Stock
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionall ... y, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
2026-07-13 09:00:00
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.
Stocks Look Shaky, But This Sector is Booming (Biotech)
2026-07-09 14:06:06
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
FTRE or ARGX: Which Is the Better Value Stock Right Now?
2026-07-07 12:41:12
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
New Strong Buy Stocks for July 7th
2026-07-07 06:45:12
DEC, FTRE, HG, PARR and KE have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2026.
Fortrea Names Jason Knoblauch as Chief Financial Officer
2026-06-26 07:00:00
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-06-10 16:15:00
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) on June 10, 2026, to 10 newly hired employees. The award consisted of 240,500 RSUs that vest in three equal annual installments starting June 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.
Fortrea to Attend Jefferies Global Healthcare Conference
2026-06-02 18:00:55
DURHAM, N. C. , June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization ("CRO"), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference: Jefferies Global Healthcare Conference (NYC)Date: Thursday, June 4, 2026Time: 8:45 AM EDTFormat: Fireside Chat To register for the live webcast, please click here.
Fortrea to Attend Jefferies Global Healthcare Conference
2026-06-02 18:00:00
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference:
Frequently Asked Questions
-
What is the current Fortrea Holdings Inc. (FTRE) stock price?
-
Fortrea Holdings Inc.(NASDAQ:FTRE) stock price is $18.03 in the last trading session. During the trading session, FTRE stock reached the peak price of $18.67 while $4.455 was the lowest point it dropped to. The percentage change in FTRE stock occurred in the recent session was 0.95% while the dollar amount for the price change in FTRE stock was $0.17.
-
FTRE's industry and sector of operation?
-
The NASDAQ listed FTRE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FTRE?
-
Leonard Scott Dove | President of Clinical Pharmacology Services
Jason F. Knoblauch | Chief Financial Officer
Hima Inguva | Head of Corporate Development
Sandy Kennedy | Chief Quality, Regulatory Affairs & Sustainability Officer
Mark A. Morais | Chief Operating Officer & President of Clinical Services -
How many employees does FTRE have?
-
Number of FTRE employees currently stands at 14300. FTRE operates from 8 Moore Drive, Durham, NC 27709, US.
-
Link for FTRE official website?
-
Official Website of FTRE is: https://www.fortrea.com
-
How do I contact FTRE?
-
FTRE could be contacted at phone #(480)-295-7600 and can also be accessed through its website. FTRE operates from 8 Moore Drive, Durham, NC 27709, US.
-
How many shares of FTRE are traded daily?
-
The average number of FTRE shares traded daily for last 3 months was 1.44M.
-
What is the market cap of FTRE currently?
-
The market value of FTRE currently stands at $1.71B with its latest stock price at $18.03